Literature DB >> 3081506

The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.

A Ichinose, K Fujikawa, T Suyama.   

Abstract

Plasma kallikrein was found to be a good activator of pro-urokinase, the inactive zymogen form of urokinase. The complete activation of pro-urokinase by plasma kallikrein was obtained in 2 h with an enzyme/substrate weight ratio of 1/30. The rate of activation of pro-urokinase by plasma kallikrein was comparable to that catalyzed by plasmin and trypsin. The rate of activation of pro-urokinase by factor XIIa was approximately one-seventh of that by plasma kallikrein. The activation of the zymogen was due to the cleavage of a single internal peptide bond, resulting in the conversion of a single chain pro-urokinase (Mr = 55,000) into two-chain urokinase (Mr = 33,000 and 22,000), and these two chains were linked by a disulfide bond(s). These results indicate an important role of plasma kallikrein for the activation of pro-urokinase in the factor XII-dependent intrinsic pathway of fibrinolysis. Thrombin also converted pro-urokinase to a two-chain form that was not activatable by plasmin, plasma kallikrein, and factor XIIa. Thrombin specifically cleaved the Arg 156-Phe 157 bond which is located 2 residues prior to the activation site of Lys 158-Ile 159.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081506

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Fibrinolytic enzymes in ascites during experimental acute pancreatitis in rats.

Authors:  Y Etoh; H Sumi; H Tsushima; M Maruyama; H Mihara
Journal:  Int J Pancreatol       Date:  1992-10

Review 3.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 5.  Recombinant natural anticoagulants: a review.

Authors:  P L Harper; J M Hermans; R W Carrell
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

6.  Plasminogen activators in ischemic stroke: introduction.

Authors:  Gregory J del Zoppo
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 7.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

8.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

9.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

Review 10.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.